What is beyond the Nivolumab Monotherapy approval for advanced Hepatocellular Carcinoma?
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 2
Abstract
With an estimated 500,000 new cases per year, hepatocellular carcinoma (HCC) represents the third leading cause of cancer death worldwide. The incidence is rising in the west, largely due to an increasing incidence of hepatitis C virus infection [1]. The majority of HCC patients are diagnosed with disease too advanced for curative treatment. Only liver resection and liver transplantation are considered curative, with poor efficiency of other modalities such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE), although this may provide a modest prolongation in survival; however, the relapse in the majority of these patients is inevitable [2]. An array of translational research and pilot clinical trials have revealed that adoptive immunotherapy's are safe by patients with HCC, but they lack efficacy [3]. Now, we are in the new era of immunotherapy's such as immune checkpoint inhibitors and CAR-T strategies, which would bring benefit to the HCC patients. On September 22, 2017, the Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol- Myers Squibb Co.) for the treatment of HCC in patients who have been previously treated with sorafenib. The approval was based on a 154-patient subgroup of CHECKMATE-040 (NCT 01658878), a multicenter, open-label trial conducted in patients with HCC and Child-Pugh.
Authors and Affiliations
Luis Mendoza
Keywords
Related Articles
- EP ID EP583053
- DOI 10.32474/OAJOM.2018.01.000109
- Views 96
- Downloads 0
Main Components of Liquid Biopsy are Greater than it Seems?
Long time ago it was wrongly thought that tumor genes and cells are only existence in the exact tumor site. In spite of the fact of the hypothesis that circulating tumor cells (CTCs) are a fundamental prerequisite to met...
Thrombosis in Iron Deficiency and Iron Deficiency Anemia: A Review of our Cases and the Relevant Literature
We evaluated our thrombosis cases for iron deficiency (ID) or iron deficiency anemia (IDA) retrospectively and reviewed the literature. We established that iron parameters were studied in 17 of 64 patients with thrombosi...
Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach
Metastatic hormone-receptor and HER-2 positive (triple-positive) breast cancer provides a treatment dilemma for clinicians. The current guidelines offer a variety of options in the first and second line for metastatic br...
Promising Role of Fractional Calculus in Biomedicine and Biophysics
The study of complex systems and investigation of their structural and dynamical properties have attracted considerable interests among scientists in general and physicists, biologists and medical researchers in particul...
Spinal Meningioma: Pathophysiology, Diagnosis and Management
Tumors have several types that can build up in or near the spine. There are many types of spinal tumors. They can appoint the spinal cord, nerve roots or the vertebrae (bones of the spine) and pelvis. Spinal tumors have...